Aadi Bioscience (AADI) Stock Forecast & Price Target

$2.22 +0.01 (+0.45%)

(As of 11/20/2024 ET)

Aadi Bioscience - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
5

Buy
0

Based on 5 Wall Street analysts who have issued ratings for Aadi Bioscience in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 5 have given a hold rating for AADI.

Consensus Price Target

$1.67
-24.92% Downside

According to the 5 analysts' twelve-month price targets for Aadi Bioscience, the average price target is $1.67. The highest price target for AADI is $1.75, while the lowest price target for AADI is $1.50. The average price target represents a forecasted downside of -24.92% from the current price of $2.22.

Get the Latest News and Ratings for AADI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Aadi Bioscience and its competitors.

AADI Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1.67	$10.25	$14.17	$34.50
Forecasted Upside	-24.92% Downside	392.79% Upside	796.62% Upside	626.32% Upside
Consensus Rating	Hold	Hold	Hold	Buy

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

AADI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AADI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Aadi Bioscience Stock vs. The Competition

Type	Aadi Bioscience	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-24.92% Downside	26,931.47% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent AADI News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	Piper Sandler Companies 5 of 5 stars		Downgrade	Overweight ➝ Neutral	$1.75
8/21/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$11.00 ➝ $1.50
8/21/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Neutral
8/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Bancroft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/11/2023	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$47.00 ➝ $33.00	+366.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:19 AM ET.

AADI Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Aadi Bioscience is $1.67, with a high forecast of $1.75 and a low forecast of $1.50.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AADI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AADI, but not buy additional shares or sell existing shares.
: According to analysts, Aadi Bioscience's stock has a predicted downside of -24.92% based on their 12-month stock forecasts.
: Over the previous 90 days, Aadi Bioscience's stock had 2 downgrades by analysts.
: Aadi Bioscience has been rated by research analysts at Piper Sandler, and Piper Sandler Companies in the past 90 days.
: Analysts like Aadi Bioscience less than other "medical" companies. The consensus rating for Aadi Bioscience is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AADI compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Financial Prophecy (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

This page (NASDAQ:AADI) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Stock Forecast & Price Target